Discover open access scientific publications

Search, annotate, share and cite publications

Publications by David R. Spigel

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

JAMA Oncology

Cancer Research

Oncology

2019

English

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

Journal of Thoracic Oncology

English

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

Journal of Thoracic Oncology

English

Brief Report: Three-Year Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC - Update From PACIFIC

Journal of Thoracic Oncology

English

Third-Line Nivolumab Monotherapy in Recurrent Small Cell Lung Cancer: CheckMate 032

Journal of Thoracic Oncology

English

Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Squamous Non–Small-Cell Lung Cancer: Results From the Randomized Controlled MONET1 Study

Journal of Thoracic Oncology

English

A Phase I Study of Weekly Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies

English

Nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2

Frontiers in Oncology

Cancer Research

Oncology

2018

English

Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-Iiia Resectable Non–Small-Cell Lung Cancer Guideline

Journal of Clinical Oncology

English

Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients With Extensive-Stage Small-Cell Lung Cancer

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by David R. Spigel

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

Brief Report: Three-Year Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC - Update From PACIFIC

Third-Line Nivolumab Monotherapy in Recurrent Small Cell Lung Cancer: CheckMate 032

Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Squamous Non–Small-Cell Lung Cancer: Results From the Randomized Controlled MONET1 Study

A Phase I Study of Weekly Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies

Nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2

Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-Iiia Resectable Non–Small-Cell Lung Cancer Guideline

Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients With Extensive-Stage Small-Cell Lung Cancer